Striverdi Respimat (Olodaterol HCl) Patent Expiration, LOE Window & CMS Spending

Striverdi Respimat (Olodaterol HCl) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2027-01-19, 0 AB generics, $5.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN203108 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-01-19
Last Listed Patent or Exclusivity Date2027-01-19
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$5.5M
2024 Medicare Part D Spend$4.9M
2024 Medicaid Spend$550K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.